Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in RB-positive metastatic hormone-sensitive prostate cancer
NCT02059213Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in prostate cancer (PCa), sponsored by University of Michigan Rogel Cancer Center. Started Jun 2014; status: completed.
02
Drugs
palbociclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02059213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059213.